Results 81 to 90 of about 1,254,871 (374)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

CRISPR-Cas

Revista de Ciência Elementar, 2023
Jorge Canhoto, Sandra Correia, Sílvia Coimbra, Ricardo Ferraz   +3 more
  +4 more sources

Use of CRISPR/Cas system in genome-editing [PDF]

, 2013
CRISPR/Cas sustav u prokariota i arheja igra važnu ulogu u obrani od infektivnih čestica. Izučavanjem principa rada CRISPR/Cas sustava ustanovljeno je da se može iskoristiti u uređivanju kako prokariotskog tako i eukariotskog genoma.
Stojanović, Mario
core   +2 more sources

Potential Application of the CRISPR/Cas9 System against Herpesvirus Infections. [PDF]

, 2018
The CRISPR/Cas9 system has been applied in the genome editing and disruption of latent infections for herpesviruses such as the herpes simplex virus, Epstein⁻Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus.
Chen, Yuan-Chuan, Liu, Fenyong, Sheng, Jingxue, Trang, Phong   +3 more
core   +2 more sources

A CRISPR-Cas Cure for HIV/AIDS

International Journal of Molecular Sciences, 2023
Human immunodeficiency virus (HIV) infections and HIV-induced acquired immunodeficiency syndrome (AIDS) continue to represent a global health burden.
Mouraya Hussein, Mariano A. Molina, B. Berkhout, E. Herrera-Carrillo   +3 more
semanticscholar   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Hutchinson Gilford Progeria Syndrome: A Therapeutic Approach via Adenoviral Delivery of CRISPR/cas Genome Editing System [PDF]

, 2014
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare human genetic disease caused by mutations in the LMNA gene. LMNA codes for structural components of the nuclear lamina. Alterations of nuclear lamina lead to a very variable class of diseases known as
ARANCIO, Walter, Genovese, SI, GIORDANO, Carla, PIZZOLANTI, Giuseppe   +3 more
core   +1 more source

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Military Medical Research, 2023
Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade.
B. Hussen, Mohammed Fatih Rasul, Snur Rasool Abdullah, H. J. Hidayat, Goran Sedeeq Hama Faraj, Fattma A. Ali, Abbas Salihi, A. Baniahmad, S. Ghafouri‐Fard, Milladur Rahman, M. Glassy, W. Branicki, M. Taheri   +12 more
semanticscholar   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems

Frontiers in Chemistry, 2022
In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications.
Faranak Hejabi, Mohammad Sadegh Abbaszadeh, Shirinsadat Taji, Andrew O’Neill, Fatemeh Farjadian, Mohammad Doroudian   +5 more
doaj   +1 more source